Galapagos and Gilead Sciences have suspended the worldwide ISABELA Phase 3 program investigating the potential of oral ziritaxestat (GLPG1690) to treat people with idiopathic pulmonary fibrosis (IPF). The decision to halt the program, which includes two identical Phase 3 trials — ISABELA 1 (NCT03711162) and ISABELA 2 (NCT03733444) — was based on recommendations of the independent data monitoring committee overseeing the studies. After reviewing data from both trials, the committee concluded that the potential benefits of ziritaxestat…

You must be logged in to read/download the full post.